The global nuclear medicine market is experiencing significant growth, valued at $12.2 billion in 2024 and projected to reach $29.8 billion by 2033, expanding at an annual rate of 10.39%. This growth is driven by rising chronic diseases, advanced imaging technologies like SPECT and PET scans, and the shift towards personalized medicine. Key applications include diagnostics in cardiology, neurology, and oncology, and therapeutic applications targeting cancer cells. North America leads the market due to its robust healthcare infrastructure, while the Asia-Pacific region is expected to grow rapidly as healthcare investments increase. Major companies in the sector include GE Healthcare, Bayer AG, and Novartis, focusing on innovation and global expansion. Challenges such as regulatory hurdles and costs remain, but opportunities exist in developing countries and new research areas. Nuclear medicine is poised to enhance healthcare by improving diagnosis and treatment efficacy.
Tue, 25 Mar 2025 17:14:15 GMT | PharmiWeb.com